Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL737082

Fc1ccc2c(c1)COC21CCN(c2ccc(OCCCN3CCCCC3)cc2)CC1.O=C(O)C(F)(F)F

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 12/20 0.47
KCNH2 Q12809 3/20 0.47
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
CACNA1B Q00975 2/20 0.44
HRH1 P35367 4/20 0.44
HTR1A P08908 3/20 0.44
DRD2 P14416 3/20 0.44
HTR2A P28223 3/20 0.44
DRD3 P35462 3/20 0.44
TMEM97 Q5BJF2 2/20 0.44
SIGMAR1 Q99720 2/20 0.44
DRD1 P21728 1/20 0.42
DRD5 P21918 1/20 0.42
KDM4E B2RXH2 1/20 0.42
S1PR5 Q9H228 1/20 0.42
CYP3A4 P08684 1/20 0.42
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL737064 0.86 HRH3 (0.46) HRH3KCNH2MAOAMAOBCACNA1B
Trifluoroacetic Acid SCHEMBL738381 0.80 HRH3 (0.61) HRH3KCNH2HRH1HTR1ADRD2
SCHEMBL738460 0.80 HRH3 (0.59) HRH3KCNH2HRH1
Trifluoroacetic Acid SCHEMBL737095 0.77 HRH3 (0.55) HRH3KCNH2CACNA1BHRH1KDM4E
Trifluoroacetic Acid SCHEMBL736467 0.77 CACNA1B (0.49) HRH3KCNH2CACNA1BHRH1KDM4E
Trifluoroacetic Acid SCHEMBL735635 0.76 HRH3 (0.57) HRH3KCNH2CACNA1BHRH1KDM4E
Trifluoroacetic Acid SCHEMBL736416 0.76 HRH3 (0.47) HRH3KCNH2CACNA1BHRH1HTR1A
Trifluoroacetic Acid SCHEMBL737476 0.76 HRH3 (0.55) HRH3KCNH2CACNA1BKDM4EPOLB
Trifluoroacetic Acid SCHEMBL735244 0.75 CACNA1B (0.47) HRH3KCNH2CACNA1BHRH1KDM4E
Trifluoroacetic Acid SCHEMBL736059 0.75 CACNA1B (0.44) HRH3KCNH2MAOAMAOBCACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138206-B2 Piperidine derivative MSD. K.K. (JP) 2012-03-20 US claimed
US-20090137576-A1 Novel Piperidine Derivative MSD K.K. (JP) 2009-05-28 US claimed
EP-1892241-A1 NOVEL PIPERIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-02-27 EP claimed
US-9949480-B2 N-alkylthio beta-lactams, alkyl-coenzyme A asymmetric disulfides, and aryl-alkyl disulfides as anti-bacterial agents UNIVERSITY OF SOUTH FLORIDA (US) 2018-04-24 US disclosed
US-20150327547-A1 N-ALKYLTHIO BETA-LACTAMS, ALKYL-COENZYME A ASYMMETRIC DISULFIDES, AND ARYL-ALKYL DISULFIDES AS ANTI-BACTERIAL AGENTS UNIVERSITY OF SOUTH FLORIDA (US) 2015-11-19 US disclosed
US-9096635-B2 N-alkylthio beta-lactams, alkyl-coenzyme A asymmetric disulfides, and aryl-alkyl disulfides as anti-bacterial agents UNIVERSITY OF SOUTH FLORIDA (US) 2015-08-04 US disclosed
US-20140235565-A1 N-ALKYLTHIO BETA-LACTAMS, ALKYL-COENZYME A ASYMMETRIC DISULFIDES, AND ARYL-ALKYL DISULFIDES AS ANTI-BACTERIAL AGENTS UNIVERSITY OF SOUTH FLORIDA (US) 2014-08-21 US disclosed
US-8722937-B2 Asymmetric disulfides and aryl-alkyl disulfides as anti-bacterial agents UNIVERSITY OF SOUTH FLORIDA (US) 2014-05-13 US disclosed
US-8138206-B2 Piperidine derivative MSD. K.K. (JP) 2012-03-20 US disclosed
US-20090137576-A1 Novel Piperidine Derivative MSD K.K. (JP) 2009-05-28 US disclosed
US-20080182815-A1 Act against several infective agents, and most notably Bacillus spp. and Staphylococcus spp., including infection caused by methicillin-resistant Staphylococcus aureus (MRSA) UNIVERSITY OF SOUTH FLORIDA 2008-07-31 US disclosed
EP-1892241-A1 NOVEL PIPERIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182815-A1 Act against several infective agents, and most notably Bacillus spp. and Staphylococcus spp., including infection caused by methicillin-resistant Staphylococcus aureus (MRSA) SQOR, TST, COASY HRH3 3934/4885KCNH2 1924/4885MAOA 349/4885
US-20090137576-A1 Novel Piperidine Derivative HRH4, HRH3, HRH1 HRH3 2/4885KCNH2 308/4885MAOA 1493/4885
US-20150327547-A1 N-ALKYLTHIO BETA-LACTAMS, ALKYL-COENZYME A ASYMMETRIC DISULFIDES, AND ARYL-ALKYL DISULFIDES AS ANTI-BACTERIAL AGENTS COASY, SQOR, TST HRH3 4602/4885KCNH2 2165/4885MAOA 418/4885
US-20140235565-A1 N-ALKYLTHIO BETA-LACTAMS, ALKYL-COENZYME A ASYMMETRIC DISULFIDES, AND ARYL-ALKYL DISULFIDES AS ANTI-BACTERIAL AGENTS COASY, SQOR, TST HRH3 4602/4885KCNH2 2165/4885MAOA 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.